Drug Discovery

Fuji Pharma acquires minority stake in Alvotech

Japan-based Fuji Pharma has acquired a 4.2% stake in biopharmaceutical firm Alvotech for around $50m.

C4XD, Horizon to develop synthetic lethality targets in oncology

C4X Discovery (C4XD) and UK-based gene editing company Horizon Discovery Group have forged an exclusive target discovery partnership in oncology.

Innovent, Incyte sign collaboration deal for three clinical-stage product candidates

Incyte and Innovent Biologics have entered into a strategic collaboration agreement for three clinical-stage product candidates discovered and developed by Incyte.

Bausch Health signs stalking horse agreement to buy Synergy Pharmaceuticals

Bausch Health Companies has signed an agreement to acquire certain assets of Synergy Pharmaceuticals in a transaction valued at around $200m plus certain assumed liabilities.

Lilly, AC Immune to collaborate on Alzheimer’s drug development

Eli Lilly and Company (Lilly) and AC Immune have signed a license and collaboration agreement, potentially worth around CHF1.89bn ($1.9bn), for research and development of tau aggregation inhibitor small molecules for the treatment of neurodegenerative diseases like Alzheimer’s disease (AD).

AMAG Pharmaceuticals to buy biopharmaceutical firm Perosphere

AMAG Pharmaceuticals has signed an agreement to acquire US-based private biopharmaceutical firm Perosphere Pharmaceuticals.

X-Chem, Almirall forge dermatology-focused drug discovery alliance

X-Chem and Almirall have partnered to discover lead compounds for innovative and challenging targets with dermatology applications.

Weizmann researchers discover new neural mechanism underlying anxiety

Researchers at the Weizmann Institute of Science in Israel have revealed a previously unknown mechanism underlying anxiety.

Schrödinger, TB Alliance collaborate to advance tuberculosis drug discovery

Schrödinger and TB Alliance have entered into a three-year research collaboration to enhance the development of next-generation tuberculosis (TB) treatments by leveraging Schrödinger’s advanced computational platform for drug discovery.